keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
L748337 is a competitive and potent β3-adrenoceptor antagonist that inhibits the action of β3-, β2-, and β1-adrenoceptors, activates MAPK signaling, promotes phosphorylation of Erk1/2, and inhibits the protective effects of CL316243, and is used in the study of disorders caused by abnormalities of the β3-adrenoceptors.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
50 mg | 6-8 weeks | $ 755.00 | |
100 mg | 6-8 weeks | $ 1,210.00 |
Description | L748337 is a competitive and potent β3-adrenoceptor antagonist that inhibits the action of β3-, β2-, and β1-adrenoceptors, activates MAPK signaling, promotes phosphorylation of Erk1/2, and inhibits the protective effects of CL316243, and is used in the study of disorders caused by abnormalities of the β3-adrenoceptors. |
Targets&IC50 | β2-adrenoceptor:204 nM (Ki), β1-adrenoceptor:390 nM (Ki), β3-adrenoceptor:4 nM (Ki) |
In vitro | The β3-adrenergic receptor selective antagonist L748337 (100nM) partially antagonized the relaxation induced by (-)-isoprenaline in cav-1KO arteries, but did not antagonize the relaxation in WT arteries[1]. |
In vivo | L748337 (5 mg/kg) exhibits anti-cancer effects in male C57BL/6 J mice (8 weeks of age) bearing syngeneic B16F10 cells[1]. |
Synonyms | L-748,337 |
Molecular Weight | 497.61 |
Formula | C26H31N3O5S |
CAS No. | 244192-94-7 |
keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20 mg/mL (40.19 mM), Sonication is recommended.
DMSO: 80 mg/mL (160.77 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
L748337 244192-94-7 GPCR/G Protein Neuroscience Adrenergic Receptor L-748,337 L 748337 L-748337 inhibitor inhibit